Your genetic code is unique. Your cancer treatment should be too.
Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.
At Kura Oncology, we are committed to realizing the promise of precision medicines for the treatment of cancer.
We are advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers.
In The News
Fierce Biotech: FDA’s renewed focus on oncology dosing spooks investors, but companies say they’re ready
June 28, 2021
Journal of Clinical Oncology: Is This the Dawn of Precision Oncology in Head and Neck Cancer?
April 20, 2021
ESMO: Tipifarnib demonstrates encouraging efficacy in patients with recurrent and/or metastatic hnscc with hras mutations
April 21, 2021
Biotech Strategy Blog: Buildings walls versus building cathedrals
October 27, 2020
Our Team
Meet some of the employees who make Kura such a great place to work.
Corporate Updates
Video
Targeting an Undruggable Oncogene: Tipifarnib and HRAS Mutant Tumors